Mo-Rez: Key Takeaways in Phase I
- Mo-Rez is an investigational antibody-drug conjugate targeting B7-H4, a protein commonly expressed in ovarian and endometrial cancers.
- Early phase 1 data from the BEHOLD-1 trial show encouraging response rates, including a 62% objective response rate in platinum-resistant ovarian cancer and a 67% response rate in recurrent or advanced endometrial cancer.
- Side effects appeared manageable in early testing. The most frequent were gastrointestinal symptoms and blood count decreases, especially neutropenia. At the highest evaluated doses, few patients stopped treatment because of side effects; dose interruptions and dose reductions were used to manage toxicity.
For women living with ovarian or endometrial cancer after standard treatments stop working, the need for better options remains urgent. A new investigational drug from GSK, called mocertatug rezetecan, or Mo-Rez, is now generating attention after early phase 1 data showed encouraging tumor responses in the two difficult-to-treat gynecologic cancers.
Mo-Rez is an antibody-drug conjugate, often called an ADC. It targets B7-H4, a protein commonly found on ovarian and endometrial cancer cells. GSK reported that B7-H4 is widely expressed in these cancers and low in normal tissues, making it a potentially useful target.
Dr. Ali Cimen, Head of Global Medical Affairs for Oncology at GSK, describes the company’s strategy as starting “with the cancer types where we have the highest unmet need” to see whether Mo-Rez can offer stronger activity with a tolerability profile doctors can manage.
The data come from the BEHOLD-1 study, an early-phase clinical trial evaluating Mo-Rez in patients with advanced cancers, including platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer. These patients often have limited treatment choices.
“We started studying this medicine in early phase clinical trials in platinum-resistant ovarian cancer, where we have a significant unmet need, and then also second-line and beyond endometrial cancer,” Dr. Cimen explains.
Because this is a phase 1 study, the findings are still early. Yet the initial results were notable.
- In patients with platinum-resistant ovarian cancer treated at the 5.8 mg/kg dose, Mo-Rez showed a 62% confirmed objective response rate.
- In recurrent or advanced endometrial cancer, the 4.8 mg/kg dose showed a 67% confirmed objective response rate.
GSK reported these response rates in its BEHOLD-1 update, and Dr. Cimen notes that responses were seen relatively quickly, as early as the first assessment point.
“This initial data was to explore the clinical signal — to show that we have efficacy and then to show that we have manageable tolerability,” Dr. Cimen says. “Those are the early data, but the data was really, really exciting.”
Next Steps
The study included several dose levels: three in platinum-resistant ovarian cancer and two in endometrial cancer. Importantly, Dr. Cimen says patients in these cohorts were not selected based on B7-H4 expression, although B7-H4 expression was seen in more than 95% of patients in the studied groups. GSK similarly reported broad B7-H4 expression in ovarian and endometrial cancers.
Side effects remain an important part of the discussion, but Dr. Cimen describes the tolerability profile as familiar to oncologists, mainly involving gastrointestinal symptoms and blood count decreases, especially neutropenia.
The most common treatment-related side effect was nausea, and more severe treatment-related side effects were mostly blood-related. At the highest evaluated doses, few patients stopped treatment because of side effects, though dose interruptions and dose reductions were used to manage toxicity.
For patients, the key message is cautious optimism. Mo-Rez is not yet an approved therapy, and larger phase 3 trials are needed to confirm whether these early responses translate into meaningful benefits such as longer cancer control, improved survival, and preserved quality of life.
Still, for cancers with limited treatment options, early signals like these matter. As Dr. Cimen puts it, the goal is to bring forward a treatment that may be more effective while remaining manageable for patients and their oncology teams.
